{"nctId":"NCT00812955","briefTitle":"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (\"Bad Cholesterol\") and Triglycerides","startDateStruct":{"date":"2008-11"},"conditions":["Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia"],"count":474,"armGroups":[{"label":"A - ABT-143 capsules 5/135 mg","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-143"]},{"label":"B - ABT-143 capsules 10/135 mg","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-143"]},{"label":"C - ABT-143 capsules 20/135 mg","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-143"]},{"label":"D - Simvastatin capsules 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: simvastatin"]}],"interventions":[{"name":"ABT-143","otherNames":[]},{"name":"simvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Participants with hypercholesterolemia and hypertriglyceridemia.\n* Participants had the following fasting lipid results following a greater than or equal to 12 hour fasting period (measured at the Screening Visit(s)):\n\n  * Triglycerides level greater than or equal to 150 milligrams/deciliter (mg/dL) and less than 400 milligrams/deciliter, and\n  * Low-density lipoprotein cholesterol greater than or equal to 160 milligrams/deciliter and less than or equal to 240 milligrams/deciliter.\n\nExclusion Criteria\n\n* Participants with certain chronic or unstable medical conditions.\n* Participants receiving coumarin anticoagulants, systemic cyclosporins, or certain other medications.\n* Pregnant or lactating women, or women intending to become pregnant.\n* Participants with diabetes mellitus that is poorly controlled.\n* Participant was of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)","description":"The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following two treatment groups:\n\nABT-143 capsules 20/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.8","spread":"1.59"},{"groupId":"OG001","value":"-47.2","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C), With ABT-143 Capsules 10/135 Milligrams Versus Simvastatin Capsules 40 Milligrams (Full Analysis Set)","description":"The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following treatment groups, ABT-143 capsules 10/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.8","spread":"1.59"},{"groupId":"OG001","value":"-46.0","spread":"1.59"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C), With ABT-143 Capsules 5/135 Milligrams Versus Simvastatin Capsules 40 Milligrams (Full Analysis Set)","description":"The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following treatment groups, ABT-143 capsules 5/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.8","spread":"1.59"},{"groupId":"OG001","value":"-38.9","spread":"1.59"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Median Percent Change in Triglycerides From Baseline to the Final Visit (Full Analysis Set)","description":"The ABT-143 capsules 20/135 milligram, ABT-143 capsules 10/135 milligram, and ABT-143 capsules 5/135 milligram groups were compared to the simvastatin capsules 40 milligram group for median percent change in triglycerides from Baseline to the Final Visit for the full analysis set.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.8","spread":null},{"groupId":"OG001","value":"-42.7","spread":null},{"groupId":"OG002","value":"-44.6","spread":null},{"groupId":"OG003","value":"-50.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to the Final Visit (Full Analysis Set)","description":"The ABT-143 capsules 20/135 milligram, ABT-143 capsules 10/135 milligram, and ABT-143 capsules 5/135 milligram groups were compared to the simvastatin capsules 40 milligram group for mean percent change in high-density lipoprotein cholesterol from Baseline to the Final Visit for the full analysis set.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"1.56"},{"groupId":"OG001","value":"16.2","spread":"1.56"},{"groupId":"OG002","value":"14.0","spread":"1.55"},{"groupId":"OG003","value":"15.7","spread":"1.56"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":119},"commonTop":["Headache","Nausea","Upper Respiratory Tract Infection"]}}}